GT Biopharma (GTBP) Change in Accured Expenses (2010 - 2026)

GT Biopharma (GTBP) has reported Change in Accured Expenses for 17 consecutive years, with $108000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 108.37% year-over-year to $108000.0; the TTM figure through Mar 2026 stood at $102000.0 (down 89.73% YoY), while the FY2025 annual figure was -$1.3 million, down 238.42% from the prior year.
• Change in Accured Expenses declined to $108000.0 in Q1 2026 per GTBP's latest filing, from $1.1 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $3.2 million in Q4 2022 and bottomed at -$3.5 million in Q3 2022.
• Historically, Change in Accured Expenses has averaged -$18823.5 across 5 years, with a median of $108000.0 in 2026.
• On a YoY basis, Change in Accured Expenses climbed as much as 2024.34% in 2022 and fell as far as 12628.57% in 2022.
• GT Biopharma's Change in Accured Expenses stood at $3.2 million in 2022, then plunged by 83.74% to $525000.0 in 2023, then jumped by 122.86% to $1.2 million in 2024, then retreated by 2.65% to $1.1 million in 2025, then plunged by 90.52% to $108000.0 in 2026.
• Business Quant data shows GTBP's Change in Accured Expenses at $108000.0 in Q1 2026, $1.1 million in Q4 2025, and -$813000.0 in Q3 2025.